Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXT3003 long-term follow-up extension in Charcot-Marie-Tooth disease type 1A
2015-002379-81Phase 3Active
- Sponsor
- Pharnext
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of baclofen, naltrexone and sorbitol in Charcot-Marie-Tooth disease type 1A (CMT1A) and Charcot-Marie-Tooth disease (CMT), sponsored by Pharnext. Primary endpoint: Incidence of treatment-emergent adverse events related to investigational product. Started Jan 2017; status: active.
02
Drugs
baclofennaltrexonesorbitol
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)Charcot-Marie-Tooth disease (CMT)
Beyond the preview
Go deeper on 2015-002379-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002379-81.